Literature DB >> 2560104

High plasma levels of cortisol in patients with senile dementia of the Alzheimer's type.

F Masugi1, T Ogihara, K Sakaguchi, A Otsuka, Y Tsuchiya, S Morimoto, Y Kumahara, S Saeki, M Nishide.   

Abstract

Plasma cortisol levels and other factors including thyroid hormone in patients with Alzheimer's type (n = 10), vascular type (n = 10) or mixed type (n = 10) senile dementia were compared with those in non-demented senile controls (n = 10). Plasma cortisol levels at 8:00 a.m. in Alzheimer's type dementia and mixed type dementia were 17.3 +/- 4.3 micrograms/dl (mean +/- SD) and 15.6 +/- 2.3 micrograms/dl, respectively. These values were significantly higher (p less than 0.005 and p less than 0.01) than those found in the control subjects (12.0 +/- 3.1 micrograms/dl). Plasma cortisol levels in vascular-type dementia (14.4 +/- 6.3 micrograms/dl) did not differ significantly from those in the controls. Plasma ACTH in senile dementia of the Alzheimer's type was lower, but not significant as compared with that in normal controls. In three subgroups of senile dementia and normal controls, plasma cortisol levels inversely correlated significantly with the degree of cognitive function. Plasma levels in TSH-thyroid system and blood pressure did not show any significant change in three types of senile dementia. These data suggest that senile dementia of the Alzheimer's type accompanies relatively and primarily high plasma cortisol levels and this may associate with cognitive dysfunction in Alzheimer's type senile dementia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2560104

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  18 in total

1.  Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.

Authors:  Kim N Green; Lauren M Billings; Benno Roozendaal; James L McGaugh; Frank M LaFerla
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

Review 2.  Aberrant expression of RCAN1 in Alzheimer's pathogenesis: a new molecular mechanism and a novel drug target.

Authors:  Yili Wu; Philip T T Ly; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

3.  Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats.

Authors:  Charleine Zussy; Anthony Brureau; Brice Delair; Stephane Marchal; Emeline Keller; Guy Ixart; Gaelle Naert; Johann Meunier; Nathalie Chevallier; Tangui Maurice; Laurent Givalois
Journal:  Am J Pathol       Date:  2011-05-10       Impact factor: 4.307

4.  Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease.

Authors:  Latha Devi; Melissa J Alldred; Stephen D Ginsberg; Masuo Ohno
Journal:  Mol Brain       Date:  2010-11-08       Impact factor: 4.041

5.  Effects of aerobic exercise on mild cognitive impairment: a controlled trial.

Authors:  Laura D Baker; Laura L Frank; Karen Foster-Schubert; Pattie S Green; Charles W Wilkinson; Anne McTiernan; Stephen R Plymate; Mark A Fishel; G Stennis Watson; Brenna A Cholerton; Glen E Duncan; Pankaj D Mehta; Suzanne Craft
Journal:  Arch Neurol       Date:  2010-01

Review 6.  Stress-induced tau phosphorylation: functional neuroplasticity or neuronal vulnerability?

Authors:  Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 7.  Stress induced neural reorganization: A conceptual framework linking depression and Alzheimer's disease.

Authors:  Jennifer A Ross; Gediminas Gliebus; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-08-10       Impact factor: 5.201

8.  Glucocorticoid Generates ROS to Induce Oxidative Injury in the Hippocampus, Leading to Impairment of Cognitive Function of Rats.

Authors:  Hiroya Sato; Takeyuki Takahashi; Kazumi Sumitani; Hirokatsu Takatsu; Shiro Urano
Journal:  J Clin Biochem Nutr       Date:  2010-10-29       Impact factor: 3.114

9.  Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients.

Authors:  Maria-Letizia Campanari; Francisco Navarrete; Stephen D Ginsberg; Jorge Manzanares; Javier Sáez-Valero; María-Salud García-Ayllón
Journal:  J Alzheimers Dis       Date:  2016-05-30       Impact factor: 4.472

10.  Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in rats.

Authors:  Charleine Zussy; Anthony Brureau; Emeline Keller; Stéphane Marchal; Claire Blayo; Brice Delair; Guy Ixart; Tangui Maurice; Laurent Givalois
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.